Indeed, the RE-DUAL PCI study actually showed a trend towards a higher rate of myocardial infarction and stent thrombosis in the subgroup of patients treated with dabigatran 110 mg twice daily + a single antiplatelet drug with a P2Y12 inhibitor, as compared to a “classical” TAT strategy including warfarin, aspirin, and a P2Y12 inhibitor [2] (this was not apparent, however, in the dabigatran 150 mg twice daily + single antiplatelet drug) [2]. Here, P2RY12 is linked to myocardial infarction.